Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
Innovative treatments for Kaposi's sarcoma (Meeting abstract).
Melanoma Res; 3:8 1993. Unique Identifier : AIDSLINE ICDB/95607236 Conant MA; University of California Medical Center, San Francisco, CA
Abstract:
New approaches in the management of Kaposi's sarcoma (KS) have been developed in the past three years, including new delivery mechanisms, autologous CD-8 expansion and cytokine development. At the Berlin AIDS Conference it was shown that 5-FU in an implant containing collagen and epinephrine was safe. The response to the placebo was as good as the response to the agent, which raises the question of the mechanism of action of the placebo. Systemic daunorubicin incorporated in liposomes has been tested for the past two years. In Berlin, Chew and Goebel reported that this combination is well tolerated and preliminary data suggest it may have great promise in targeting the lesions of KS in high doses while sparing the patient from some toxic side effects. At last year's AIDS Conference, autologous CD-8 cell expansion was reported to show dramatic benefit in one patient with KS. In Berlin, Klimas reported that five out of six patients showed partial responses as defined by 25% lesion reduction with ex vivo CD-8 expansion reinfusion and infusion of IL-2. Unfortunately, when patients were receiving expanded CD-8 cells, new lesions of KS were observed. Last year, oncostatin-M appeared to be involved in the proliferation of KS in vitro; stimulating interest in identifying cytokines and growth factors possibly responsible for its development. Huang et al recently demonstrated that growth factor FGF-5 could be identified in four out of six patients with KS, but not in the adjacent normal skin of the same patient. This finding suggests that this growth factor may play a role in the pathogenesis of KS. The identification of the growth factor or cytokine responsible for KS will create the possibility of blocking this agent, using appropriate recombinant technology.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Cytokines/PHYSIOLOGY Fibroblast Growth Factor/PHYSIOLOGY Human Sarcoma, Kaposi's/ETIOLOGY/METABOLISM/PATHOLOGY/*THERAPY *T-Lymphocytes, Suppressor-Effector Tumor Cells, Cultured ABSTRACT 950730
M9570951
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
